Abstract
IGF-II is a regulatory peptide which appears to be involved significantly in the progression of many tumors, while minimally involved in post-fetal non-tumor tissue. Interruption of IGF-II pathways therefore offers the possibility of tumor control with a high therapeutic index. Investigators should continue to evaluate tumors for the involvement of IGF-II as well as investigate clinically relevant means of disrupting those pathways.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Cell Membrane / metabolism
-
Genomic Imprinting
-
Humans
-
Insulin-Like Growth Factor Binding Proteins / metabolism
-
Insulin-Like Growth Factor II / genetics
-
Insulin-Like Growth Factor II / physiology*
-
Neoplasms / etiology*
-
Neoplasms / metabolism
-
Neoplasms / therapy
-
Receptor, IGF Type 2 / metabolism
-
Signal Transduction / physiology*
-
Transcription, Genetic
-
Transcriptional Activation
Substances
-
Insulin-Like Growth Factor Binding Proteins
-
Receptor, IGF Type 2
-
Insulin-Like Growth Factor II